Polyarticular Juvenile Rheumatoid Arthritis

Arthritis, Juvenile Idiopathic

Click here for more information on the Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

University of Alabama at Birmingham

Stanford University Medical Center

Rady Children's Hospital-San Diego

University of California at San Francisco Medical Center

Children's Hospital Colorado

Connecticut Children's Medical Center

University of Florida Shand's Children's Hospital

Emory Children's Center

Georgia Regents University Medical Center

Ann & Robert H. Lurie Children's Hospital of Chicago

University of Chicago Medical Center

Indiana University School of Medicine

University of Iowa Hospitals and Clinics

University of Kansas Medical Center

University of Louisville School of Medicine

Tufts Medical Center

Boston Children's Hospital

Baystate Medical Center, High Street Health Center

University of Michigan Medical Center

University of Minnesota

Mayo Clinic

Children's Mercy Hospital

Saint Louis University School of Medicine

Saint Louis Children's Hospital

HackensackUniversity Medical Center

Goryeb Children's Hospital

Pediatric Specialty Center at Saint Barnabas

Albany Medical College

Children's Hospital at Montefiore

Cohen Children's Medical Center of New York

New York University Langone Medical Center

Hospital for Special Surgery

Columbia University Medical Center

Levine Children's Hospital

Duke Children's Hospital & Health Center

Cincinnati Children's Hospital Medical Center

MetroHealth Medical Center

UH Rainbow Babies and Children's Hospital

Clevland Clinic Foundation

Nationwide Children's Hospital

Randall Children's Hospital at Legacy Emanuel

Children's Hospital of Philadelphia

St. Christopher's Hospital for Children

Children's Hospital of Pittsburgh of UPMC

Medical University of South Carolina Children's Hospital

Monroe Carell Jr. Children's Hospital at Vanderbilt

University of Texas Southwestern Medical Center Dallas

Baylor College of Medicine Pediatric Immunology, Allergy and Rheumatology

University of Utah Hospitals and Clinics

University of Vermont Medical Center

Seattle Children's Hospital

University of Wisconsin-American Family Children's Hospital

University of Calgary- Alberta Children's Hospital

IWK Health Center

The Hospital for Sick Children

Start Time Optimization of Biologics in Polyarticular JIA

We will use the American College of Rheumatology criteria for CID to compare achievement of CID between the groups started on the 3 CTPs

We will use The Patient Reported Outcomes Measurement Information System (PROMIS), to compare patient and caregiver reported outcomes between the groups started on the 3 CTPs

Hackensack Meridian Health

Patient-Centered Outcomes Research Institute

Childhood Arthritis and Rheumatology Research Alliance

Duke Clinical Research Institute

Boston Children’s Hospital

University Health Network, Toronto

Biosample collection is active for a subset of subjects within the registry

Rheumatic Joint Disease

Phoenix Children's Hospital

Mattel Children's Hospital at University of California Los Angeles

Rady Children's Hospital San Diego

The Children's Hospital of Colorado

Yale University

Childrens National Medical Center

University of Florida - Shand's Children's Hospital

Nicklaus Children's Hospital

Nemours Children's Hospital

Johns Hopkins All Children's Hospital

University of Illinois at Chicago

The University of Iowa Hospitals and Clinics (University of Iowa Children's Hospital)

University of Louisville Schoole of Medicine

Massachusetts General Hospital for Children

Bay State Medical Center

University of Michigan

Helen Devos Children's Hospital

West Michigan Rheumatology

Hackensack University Medical Center

Robert Wood Johnson Medical School

The Pediatric Specialty Center at Saint Barnabas

University of North Carolina at Chapel Hill

Levine Children's Hospital / Carolinas Medical Center

Wake Forest Baptist Brenner Children's Hospital

Sanford Health

Akron Children's Hospital

UH Rainbox Babies and Children's Hospital

Metrohealth Medical Center

Cleveland Clinic Foundation

Penn State Children's Hospital

Saint Christopher's Hospital for Children

Children's Hospital of Pittsburgh UPMC

Hasbro Children's Hospital

Monroe Carrell Jr. Children's Hospital at Vanderbilt

Baylor College of Medicine Pediatric Immunology Allergy Rheumatology

University of Utah Hospitals and Clinics (Primary Children's Hospital)

University of Wisconsin, American Family Children's Hospital

Children's Hospital Of Wisconsin

University of Calgary - Alberta Children's Hospital

University of Manitoba - Children's Hospital of Manitoba

San Jorge Children's Hospital

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Duke University

Systemic Lupus Erythematosus (SLE)

Baylor Institute for Immunology Research

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

Pilot Study in Children With Systemic Lupus Erythematosus (SLE) to Assess Flares and to Measure Traditional and Novel Blood Biomarkers and Antibody Titers Following Receipt of Inactivated Influenza Vaccine (IIV)

Ability to recruit the entire sample cohort of 30 subjects during the pre-planned enrollment period.
Eighty percent of subjects complete all blood draws within the designated time frame
Adherence to protocol for blood collection, reaction assessment, clinic follow up, and laboratory analysis for 80% of the enrolled cohor

To ascertain the ability to detect flares and associate the flare to vaccine
To correlate post-vaccine changes in blood biomarkers with the development of flares as assessed by SLEDAI and BILAG scores as well as self- and physician-assessed reactogenicity

To ascertain the development of neutralizing and hemagglutination inhibition (HAI) antibody titers at baseline and at 28 days (+ 7 day)
To correlate changes in blood biomarkers with response to vaccine using immune profiling analysis.

Kathryn Edwards

Professor of Pediatrics

Vanderbilt University

Vanderbilt University Medical Center

Baylor Research Institute

Centers for Disease Control and Prevention

Specimens currently being collected from subjects with juvenile dermatomyositis JDM), systemic juvenile idiopathic arthritis (sJIA), and localized scleroderma.

Juvenile Idiopathic Arthritis

Systemic Lupus Erythematosus

Mixed Connective Tissue Disease

Juvenile Ankylosing Spondylitis

Juvenile Dermatomyositis

Localized Scleroderma

Systemic Sclerosis

Vasculitis

Sarcoid

Fibromyalgia, Primary

Auto-inflammatory Disease

Idiopathic Uveitis Idiopathic

The CARRA Registry

This is an observational registry. The primary outcome is the # of subjects enrolled with pediatric rheumatic disease.

National Institutes of Health (NIH)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Arthritis Foundation

Lupus Foundation of America

Cure JM Foundation

Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.

Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.

Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
Atorvastatin : Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.

1 Atorvastatin

Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
Placebo atorvastatin : Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.

2 Placebo

Total

Sex: Female, Male

For the common carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right common near wall mean, right common far wall mean, left common near wall mean and left common far wall mean). These summary variables were then averaged to estimate a single mean-mean common CIMT for each participant visit.

Change in Mean-Mean Common Carotid IMT (CIMT)

For each side, segment and wall, the maximum CIMT over the 4 angles of interrogation was selected to produce 12 summary variables (right common near wall max, right common far wall max, right bifurcation near wall max, right bifurcation far wall max, right internal near wall max, right internal far wall max, left common near wall max, left common far wall max, left bifurcation near wall max, left bifurcation far wall max, left internal near wall max and left internal far wall max). These 12 summary variables were then averaged to estimate a single mean-max CIMT for each participant visit.

Change in Mean-Max CIMT

For each side, segment and wall, mean CIMT values were averaged over the 4 angles of interrogation to produce 12 summary variables (right common near wall mean, right common far wall mean, right bifurcation near wall mean, right bifurcation far wall mean, right internal near wall mean, right internal far wall mean, left common near wall mean, left common far wall mean, left bifurcation near wall mean, left bifurcation far wall mean, left internal near wall mean and left internal far wall mean). These 12 summary variables were then averaged to estimate a single mean-mean CIMT for each participant visit.

Change in Mean-Mean CIMT

For each side and wall of the common carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right common near wall max, right common far wall max, left common near wall max and left common far wall max). These summary variables were then averaged to estimate a single mean-max common CIMT for each participant visit.

Change in Mean-Max Common CIMT

For each side and wall of the internal carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right internal near wall max, right internal far wall max, left internal near wall max and left internal far wall max). These summary variables were then averaged to estimate a single mean-max internal CIMT for each participant visit.

Change in Mean-Max Internal CIMT

For the internal carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right internal near wall mean, right internal far wall mean, left internal near wall mean and left internal far wall mean). These summary variables were then averaged to estimate a single mean-mean internal CIMT for each participant visit.

Change in Mean-Mean Internal CIMT

For each side and wall of the bifurcation arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right bifurcation near wall max, right bifurcation far wall max, left bifurcation near wall max and left bifurcation far wall max). These summary variables were then averaged to estimate a single mean-max bifurcation CIMT for each participant visit.

Change in Mean-Max Bifurcation CIMT

For the bifurcation arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right bifurcation near wall mean, right bifurcation far wall mean, left bifurcation near wall mean and left bifurcation far wall mean). These summary variables were then averaged to estimate a single mean-mean bifurcation CIMT for each participant visit.

Change in Mean-Mean Bifurcation CIMT

For the far wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common far wall max, right bifurcation far wall max, right internal far wall max, left common far wall max, left bifurcation far wall max, and left internal far wall max). These 6 summary variables were then averaged to estimate a single mean-max far wall CIMT for each participant visit.

Change in Mean-Max Far Wall CIMT

For the far wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common far wall mean, right bifurcation far wall mean, right internal far wall mean, left common far wall mean, left bifurcation far wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit.

Change in Mean-Mean Far Wall CIMT

For the near wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common near wall max, right bifurcation near wall max, right internal near wall max, left common near wall max, left bifurcation near wall max, and left internal near wall max). These 6 summary variables were then averaged to estimate a single mean-max near wall CIMT for each participant visit.

Change in Mean-Max Near Wall CIMT

For the near wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common near wall mean, right bifurcation near wall mean, right internal near wall mean, left common near wall mean, left bifurcation wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit.

Change in Mean-Mean Near Wall CIMT

Change in Natural Log of mg/L for hsCRP

Change in Total Cholesterol

Change in HDL Cholesterol

Change in LDL Cholesterol

Change in Triglycerides

Change in Lipoprotein A

Change in Homocysteine

Overall Study

Laura Schanberg, MD

Lupus Erythematosus, Systemic

Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.

Atorvastatin

Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.

Placebo atorvastatin

Duke Medical Center / Duke Clinical Research Institute

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE

mercurialis monoica/arthritis

Start Time Optimization of Biologics in Polyarticular JIA

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

The CARRA Registry

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

科学支持的最完整的草药数据库